Author:
Mina Roberto,Petrucci Maria Teresa,Bonello Francesca,Bongarzoni Velia,Saccardi Riccardo,Bertuglia Giuseppe,Mengarelli Andrea,Spadaro Andrea,Lisi Chiara,Curci Paola,Lemoli Roberto Massimo,Ballanti Stelvio,Floris Rita,Cupelli Luca,Tosi Patrizia,Olivieri Attilio,Rota-Scalabrini Delia,Cangialosi Clotilde,Nozzoli Chiara,Anaclerico Barbara,Fazio Francesca,Bruno Benedetto,Mancuso Katia,Corradini Paolo,Milone Giuseppe,Boccadoro Mario
Abstract
High-dose melphalan plus autologous stem-cell transplantation (ASCT) is a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), and adequate hematopoietic stem-cell (HSC) collection is crucial to ensure hematologic recovery after ASCT.
In this prospective, observational study we evaluated HSC mobilization with granulocyte colony-stimulating factor (G-CSF), cyclophosphamide, and ‘on-demand’ plerixafor (in patients with
Publisher
Ferrata Storti Foundation (Haematologica)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献